225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient. (May 2021)

• Record Type: Journal Article
• Authors: Aras, Omer; Harmsen, Stefan; Ting, Richard; Sayman, Haluk B
• Is Part Of: Acta radiologica open. Volume 10:Number 5(2021)
• Publication Date: 2021-05
• Subjects: 225Ac-PSMA -- metastatic prostate cancer -- radioligand therapy -- genetic alterations; Radiology -- Periodicals; Diagnostic Imaging -- Periodicals; Radiology; Periodicals; 616.075705
• DOI: 10.1177/20584601211022509
• Languages: English
• ISSNs: 2058-4601

Abstract

Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225 Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177 Lu-PSMA-617. In addition, the patient's baseline germline mutation likely predisposed him to more aggressive disease.